Ligand Purchases Palvella’s Royalty Rights and Milestone Payments of PTX-022 for Pachyonychia Congenita

 Ligand Purchases Palvella’s Royalty Rights and Milestone Payments of PTX-022 for Pachyonychia Congenita

Ligand Purchases Palvella’s Royalty Rights and Milestone Payments of PTX-022 for Pachyonychia Congenita

Shots:
  • Palvella will receive $10M as total deal value from Ligand, and will be responsible for PTX-022
    development and commercialization. Ligand to get milestones and royalties on sales of PTX-022
  • The focus of the agreement is to develop PTX-022 for its approval, with its expected launch in 2022. In Nov, 2018 PTX-022 has received FDA’s ODD and Fast Track Designation for Pachyonychia Congenita
  • PTX-022 is a topical formulation of rapamycin mTOR inhibitor developed using Palvella’s Qtorin technology, evaluated in P-II/III for pachyonychia congenita

Click here to read full press release/ article | Ref: Ligand Pharmaceuticals | Image: Fortune

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post